[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632331":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":36,"centralContacts":47,"locations":53,"responsibleParty":67,"collaborators":36,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":72,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":36,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":96,"whyStopped":36,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"University of Gaziantep","OTHER",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Ibuprofen","EXPERIMENTAL","Participants receive ibuprofen prior to ESWL for pain control.",[13],"Drug: Ibuprofen (Brufen®)",{"label":15,"type":10,"description":16,"interventionNames":17},"Paracetamol","Participants receive paracetamol prior to ESWL for pain control.",[18],"Drug: Paracetamol (drug)",{"label":20,"type":10,"description":21,"interventionNames":22},"Tenoxicam","Participants receive tenoxicam prior to ESWL for pain control.",[23],"Drug: Placebo",{"label":25,"type":26,"description":27,"interventionNames":28},"Placebo","PLACEBO_COMPARATOR","Participants receive placebo prior to ESWL.",[29],"Drug: Tenoxicam",[31,37,41,44],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DRUG","Ibuprofen (Brufen®)","Ibuprofen administered prior to ESWL for pain control.",[9],null,{"type":32,"name":38,"description":39,"armGroupLabels":40,"otherNames":36},"Paracetamol (drug)","Paracetamol administered prior to ESWL for pain control.",[15],{"type":32,"name":20,"description":42,"armGroupLabels":43,"otherNames":36},"Tenoxicam administered prior to ESWL for pain control.",[25],{"type":32,"name":25,"description":45,"armGroupLabels":46,"otherNames":36},"Placebo administered prior to ESWL.",[20],[48],{"name":49,"role":50,"phone":51,"phoneExt":36,"email":52},"Mehmet Öztürk","CONTACT","+905393328554","mehmetozturk000@gmail.com",[54],{"facility":55,"status":36,"city":56,"state":57,"zip":36,"country":58,"countryCode":36,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Gaziantep University Faculty of Medicine Hospital","Gaziantep","Turkey","Turkey (Türkiye)",{"type":60,"coordinates":61},"Point",[62,63],37.3825,37.05944,{"lat":63,"lon":62},[66],{"name":49,"role":50,"phone":51,"phoneExt":36,"email":52},{"type":68,"investigatorFullName":49,"investigatorTitle":69,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"PRINCIPAL_INVESTIGATOR","Asst. Prof. Dr.","100632331","phase-4-pain-control-during-eswl-using-non-opioid-analgesics-100632331",false,"NCT07512297","Pain Control During ESWL Using Non-Opioid Analgesics","Comparative Evaluation of Non-Opioid Analgesics for Pain Control During Extracorporeal Shock Wave Lithotripsy: A Prospective Randomized Controlled Trial","ESWL-PAIN","Inclusion Criteria:\n\n* Adult patients (≥18 years) undergoing ESWL for urinary stone disease\n* Patients with kidney or ureteral stones indicated for ESWL\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Known hypersensitivity or contraindication to ibuprofen, paracetamol, or tenoxicam\n\n  * Chronic pain conditions or regular use of analgesics\n  * Pregnancy or breastfeeding\n  * Severe renal or hepatic impairment\n  * Patients unable to complete pain assessment using VAS","ALL","18 Years","75 Years",{"count":82,"type":83},160,"ESTIMATED","INTERVENTIONAL",[86],"PHASE4","This prospective randomized controlled trial aims to compare the analgesic efficacy of three non-opioid analgesics (ibuprofen, paracetamol, and tenoxicam) during extracorporeal shock wave lithotripsy (ESWL). All patients undergoing ESWL will be randomly assigned into four groups including a placebo group.\n\nPain intensity will be assessed using the Visual Analog Scale (VAS) at the 5th, 10th, 15th, and 20th minutes during the procedure. In addition to comparing analgesic efficacy, the study will evaluate patient-related and stone-related factors affecting pain perception, including body mass index, subcutaneous fat thickness, and stone density measured by Hounsfield Units.\n\nThe study also aims to assess the relationship between analgesic efficacy, energy levels applied during ESWL, and treatment outcomes such as stone-free rates. The findings may contribute to optimizing individualized pain management strategies and improving treatment efficiency in ESWL procedures.",[89,90,91],"Urolithiasis","Kidney Stones","Ureteral Stones",[93,94,95],"ESWL","pain","Analgesia","NOT_YET_RECRUITING","2026-04-05",{"date":99,"type":100},"2026-04-09","ACTUAL",{"date":102,"type":83},"2026-04-01",{"date":104,"type":83},"2027-03-01",{"name":5,"class":6},1]